The changing face of treatment for Crohn's disease.
Department of Medicine, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium. severine.vermeire@uz.kuleuven.ac.be
S
S
Vermeire
P
P
Rutgeerts
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D015815:Cell Adhesion Molecules / Q000378:metabolism; D002986:Clinical Trials as Topic; D003424:Crohn Disease / Q000628:therapy*; D016207:Cytokines / Q000627:therapeutic use; D005765:Gastrointestinal Agents / Q000378:metabolism; D006801:Humans; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced; D000069442:Natalizumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015815:Cell Adhesion Molecules; D016207:Cytokines; D005765:Gastrointestinal Agents; D000069442:Natalizumab